THERMO FISHER SCIENTIFIC INC
TMONYSETrading Snapshot
- Day Range
- $295.15 β $301.61
- 52-Week Range
- $435.27 β $682.98
- Volume
- $7.01B
- Avg Volume
- $7.07B
- Shares Outstanding
- 369.7M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $44.56B
- Last Q Revenue
- $11.99B
- P/E Ratio
- 36.3
- P/S Ratio
- 5.4x
- EPS (TTM)
- $18.81
- Dividend Yield
- 0.27%
- Dilution (1yr)
- β1.6%
Why Investors Own TMO
- βHigh-growth profile β revenue up +44.1% YoY with expanding US Equity exposure.
- βHealthy economics β 58% gross margin and 13% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
THERMO FISHER SCIENTIFIC INC
TMOAbout THERMO FISHER SCIENTIFIC INC
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
THERMO FISHER SCIENTIFIC INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TMO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
THERMO FISHER SCIENTIFIC INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.